Author + information
- Received April 22, 1991
- Revision received July 23, 1991
- Accepted August 20, 1991
- Published online March 1, 1992.
- Thomas C. Wall, MD, FACC1,
- Robert M. Califf, MD, FACC1,
- Barry S. George, MD, FACC*,1,
- Stephen G. Ellis, MD, FACC†,1,
- Joseph K. Samaha, MD, FACC‡,1,
- Dean J. Kereiakes, MD, FACC§,1,
- Seth J. Worley, MD, FACC‖,1,
- Kristina Sigmon1,
- Eric J. Topol, MD, FACCΨ,¶,1,
- TAMI-7 study group
- ↵ΨAddress for reprints: Eric J. Topol, MD, The Cleveland Clinic Foundation, One Clinic Center, 9500 Euclid Avenue, Cleveland, Ohio 44195.
To determine the clinical profile and efficacy of accelerated recombinant tissue-type plasminogen activator (rt-PA) dose regimens, five different strategies of thrombolytic therapy in a total of 232 patients were systematically evaluated in the setting of acute myocardial infarction. The fifth strategy involved a combination of accelerated rt-PA and intravenous urokinase (regimen E). A weight-adjusted dose of 1.25 mg/kg body weight of tissue plasminogen activator over 90 min (regimen C) yielded the highest coronary patency rate (83%) at acute angiography. The associated in-hospital reocclusion rate for this regimen was low (4%). An exaggerated (60-min) dosage regimen yielded an inferior coronary patency rate (63%). Combination therapy (regimen E) was associated with a 72% patency rate and 3% reocclusion rate.
Marginal improvement in global ejection fraction and regional wall function was demonstrated with all strategies by predischarge catheterization. Bleeding complications were most common at the periaccess site and were not different from those in previous experiences reported with conventional 3-h dosing regimens.
Measurements of baseline, 30-min and 3-h levels of tissue plasminogen activator, fibrinogen and fibrin(ogen) degradation products were obtained. At 3 h, fibrinogen levels of <1 g/liter were demonstrated with combination therapy (regimen E) as well as with regimen C. Major clinical outcomes including death, reocclusion and reinfarction also showed a tendency to be less common with regimen C.
Therefore, although accelerated dose regimens of rt-PA do not reliably yield acute coronary patency rates >85%, an acute coronary patency rate of approximately 85% can be approached. However, exaggerated (60-min) accelerated therapy may be associated with inferior coronary patency rates compared with conventional regimens.
The profile of heightened velocity of reperfusion, low reocclusion rates and a bleeding complication frequency comparable with that with conventional thrombolytic regimens suggests that accelerated rt-PA therapy deserves more extensive investigation.
- Received April 22, 1991.
- Revision received July 23, 1991.
- Accepted August 20, 1991.
- American College of Cardiology Foundation